Opendata, web and dolomites

NO-GO SIGNED

NO-GO: UNVEILING THE POWER OF C-08 FOR THE TREATMENT OF OVER ACTIVE BLADDER

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NO-GO project word cloud

Explore the words cloud of the NO-GO project. It provides you a very rough idea of what is the project "NO-GO" about.

archangelica    obtain    oab    expensive    starting    efsa    drugs    save    gt    healthcare    normal    bodies    trial    iso    clinically    prevalence    patients    seize    population    worldwide    validated    complying    launched    vitro    validation    characterization    rates    benefit    natura    efficiency    75    standards    symptoms    america    treatments    regulate    roi    angelica    saga    embarrassment    landscape    urgency    urinary    ecosystem    natural    doctors    2005    vivo    social    tune    2021    psychological    expansion    nocturia    108    prescription    impaired    jobs    iceland    30    21    syndrome    anxiety    precursor    too    north    day    sagapro    small    gmp    66    profits    recommend    prepared    fine    16    performed    life    mass    500    improvement    depression    formulation    over    age    bladder    cultivating    multiple    sustainable    demonstrating    claims    80    icelandic    million    internalize    health    active    effect    extend    minimizing    dropout    safety    10    made    opportunity    business    market    capacity    relaxing    pharmacological    plant    people    leaves    create    clinical    preserving    selling    interactions   

Project "NO-GO" data sheet

The following table provides information about the project.

Coordinator
SAGANATURA EHF 

Organization address
address: SUDURHELLU 8
city: HAFNARFJORDUR
postcode: 221
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Iceland [IS]
 Total cost 2˙232˙470 €
 EC max contribution 1˙562˙729 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2021-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SAGANATURA EHF IS (HAFNARFJORDUR) coordinator 1˙562˙729.00

Map

 Project objective

Over Active Bladder (OAB) is a syndrome characterized by several urinary symptoms, like urgency and nocturia. Prevalence is >10% of the population, 500 million people worldwide, and increases with age (>30% over 75 years old). OAB has psychological consequences such as embarrassment, impaired social interactions, depression and anxiety. Current pharmacological treatments for OAB are associated with multiple side effects and 80% dropout rates within 1 year. At Saga Natura we have developed NO-GO, a natural product for improving OAB symptoms, made from the leaves of the Icelandic plant Angelica archangelica. NO-GO’s precursor SagaPro was launched on the market in 2005, becoming Iceland’s top-selling non-prescription urinary product. We have performed in vivo and in vitro characterization of SagaPro’s bladder relaxing effect and we have clinically validated SagaPro in a small-scale clinical trial on 66 OAB patients, demonstrating it’s efficiency and safety. In Phase 2 we want to fine-tune our formulation, increase and internalize our production capacity complying with ISO and GMP standards and extend our clinical validation. We will also regulate NO-GO through the EFSA to obtain health claims. This way we will be prepared for our product’s mass expansion in Europe and in North America starting in 2021. This project will create 21 new jobs and profits of €108 Million with ROI of 16.6 after 5 years on the market. End-users will benefit from improvement of symptoms, no side effects, and ability to lead a normal every day life. Doctors will be able to recommend NO-GO to their OAB patients, a product with no side effects, and healthcare bodies will save costs on expensive OAB prescription drugs with too high dropout rates. Finally, with our sustainable approach for cultivating Angelica archangelica we will seize this business opportunity while also preserving the Icelandic landscape, using natural resources and minimizing the impact to the ecosystem.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NO-GO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NO-GO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

STURSKIN (2018)

Innovative products by using tanned sturgeon skin

Read More  

APS (2019)

On-site and On-demand Flexible Packaging System

Read More  

VAL (2019)

tle Easy identification of optimal translators in a global digital marketplace

Read More